

# Supplementary Information




## **Matrix viscoelasticity controls spatio-temporal tissue organization**

Alberto Elosegui-Artola, Anupam Gupta, Alexander J. Najibi, Bo Ri Seo, Ryan Garry, Max Darnell, Wei Gu, Qiao Zhou, David A. Weitz, L. Mahadevan, David J. Mooney

Supplementary information included in this file:

- Extended Data Figures 1 to 15.
- Supplementary methods.
- Supplementary text describing the model.
- Supplementary Tables 1 to 3.



1



2

3 **Extended Data Figure 1.** Matrix Viscoelasticity regulates tissue growth and geometry. Examples of  
4 growth of MCF10A spheroids in elastic versus viscoelastic hydrogels over 5 days. Phalloidin in cyan,  
5 Hoechst in magenta. **b-c**, Quantification of spheroids area (**b**) and circularity (**c**) after 5 days with or  
6 without focal adhesion kinase (FAK) inhibitor PF 573228.  $n=56,27,41,23$  spheroids per condition. Statistical  
7 analysis was performed using Kruskal–Wallis test followed by post hoc Dunn’s test. All data represent  
8 mean  $\pm$  s.d.; all scale bars represent 200  $\mu\text{m}$ .

9




10


11 **Extended Data Figure 2. Viscoelasticity increases tumor growth in mice. a-b,** Quantification of MDA-  
 12 MB-231 tumor volume evolution in NOD/SCID mice. MDA-MB-231 cells encapsulated in elastic (a) and  
 13 viscoelastic (b) alginate gels were injected subcutaneously into mouse flanks and tumor growth was  
 14 tracked externally using calipers. Each curve represents an independent tumor/mouse.

15


a



b




c



16


17 **Extended Data Figure 3. 3D model for stress dependent cell flux simulations.** a, The texts in light  
 18 blue/light red color boxes describe the matrix/cell property and interactions therein. The yellow boxes  
 19 represent the parameters which we vary to probe the phase space of morphologies. In this case the cell  
 20 proliferation is stress dependent, hence cell flux is material property dependent. b, Volume of the tissue  
 21 as a function of time for the elastic ( $A = \frac{\tau_a}{\tau_m} = 0.4, \mu = \frac{\mu_t}{\mu_m} = 0.002, j = \frac{\tau_g}{\tau_t} = 0.05$ ) and viscoelastic  
 22 ( $A = \frac{\tau_a}{\tau_m} = 400, \mu = \frac{\mu_t}{\mu_m} = 2, j = \frac{\tau_g}{\tau_t} = 0.22$ ) matrices (c) sphericity of the tissue as a function of time  
 23 for elastic ( $A = \frac{\tau_a}{\tau_m} = 0.4, \mu = \frac{\mu_t}{\mu_m} = 0.002, j = \frac{\tau_g}{\tau_t} = 0.05$ ) and viscoelastic ( $A = \frac{\tau_a}{\tau_m} = 400, \mu = \frac{\mu_t}{\mu_m} =$   
 24  $2, j = \frac{\tau_g}{\tau_t} = 0.22$ ) matrices.



25


26 **Extended Data Figure 4. Cell motility regulates tissue growth, symmetry breaking and branching. a-b,**  
 27 Model prediction of spheroids projected area (a) and circularity (b) evolution with time when cell  
 28 motility is suppressed, for stiff elastic ( $A = \frac{\tau_a}{\tau_m} = 0.03, \mu = \frac{\mu_t}{\mu_m} = 0.002, j = \frac{\tau_g}{\tau_t} \sim 0$ ) and stiff viscoelastic  
 29 ( $A = \frac{\tau_a}{\tau_m} = 33.3, \mu = \frac{\mu_t}{\mu_m} = 2, j = \frac{\tau_g}{\tau_t} \sim 0$ ). **c,** Quantification of spheroids circularity after 5 days in  
 30 hydrogels with and without cell adhesive ligand RGD.  $n=52,52,51,54$  spheroids per condition. Statistical  
 31 analysis was performed using Kruskal–Wallis test followed by post hoc Dunn’s test. **d,** Representative  
 32 images (upper row) and quantification of spheroids circularity (lower row) after 5 days in hydrogels in

33 the presence of the indicated inhibitors. n=52,50,51,51,51,50,51,50,51,46,41,51 spheroids per condition.  
34 Statistical analysis was performed using Kruskal–Wallis test followed by post hoc Dunn’s test. (e),  
35 Representative images (upper row) and quantification of spheroid’s circularity (lower row) after 5 days  
36 hydrogels in the presence of the indicated inhibitors. n=21,21,24,20,21,25 spheroids per condition.  
37 Statistical analysis was performed using Kruskal–Wallis test followed by post hoc Dunn’s test. All data  
38 represent mean  $\pm$  s.d.; all scale bars represent 200  $\mu$ m.



39


40 **Extended Data Figure 5. Cell proliferation is required for tissue growth, symmetry breaking and**  
 41 **branching. a-b,** Quantification from the simulations of the projected area (a) and circularity (b) of the  
 42 spheroids, respectively, over time when proliferation is inhibited, for stiff elastic ( $A = \frac{\tau_a}{\tau_m} = 0.4, \mu =$   
 43  $\frac{\mu_t}{\mu_m} = 0.002, j = \frac{\tau_g}{\tau_t} = 0$ ) and stiff viscoelastic ( $A = \frac{\tau_a}{\tau_m} = 400, \mu = \frac{\mu_t}{\mu_m} = 2, j = \frac{\tau_g}{\tau_t} = 0$ ) matrices. c,  
 44 Quantification of the circularity of spheroids without or in the presence of thymidine to inhibit cell  
 45 proliferation. n=52,53,51,53 spheroids per condition. Statistical analysis was performed using Kruskal–  
 46 Wallis test followed by post hoc Dunn’s test. All data represent mean  $\pm$  s.d.



47


48 **Extended Data Figure 6. Cell proliferation is required for tissue growth, symmetry breaking and**  
 49 **branching.** **a**, Simulation and Experimental results for the distribution of proliferating cells across  
 50 spheroids in elastic (upper row) and viscoelastic gels (lower row): left, simulation example of the daughter  
 51 cells (cyan) and the cells in the tissue spheroid (yellow elastic and cyan viscoelastic); center, representative  
 52 examples of experimental spheroids showing EdU positive cells (cyan) and cell nuclei (Hoechst, magenta)  
 53 for spheroids; right, colormaps showing the local percentage of Edu positive cells across the spheroid. **b-**  
 54 **c**, Experimental (**b**) and simulation results (**c**) showing the density proliferating cells depending of distance  
 55 from the spheroid edge.  $n=3,4$  spheroids per condition. Error bars are s.e.m. All scale bars are  $200\ \mu\text{m}$ . **d**,  
 56 The normalized stress energy estimated from the simulations depending on the distance from the  
 57 spheroid edge. The dimensionless parameter in the model for stiff elastic ( $A = \frac{\tau_a}{\tau_m} = 0.4, \mu = \frac{\mu_t}{\mu_m} =$   
 58  $0.002, j = \frac{\tau_g}{\tau_t} = 0.05$ ) and stiff viscoelastic ( $A = \frac{\tau_a}{\tau_m} = 400, \mu = \frac{\mu_t}{\mu_m} = 2, j = \frac{\tau_g}{\tau_t} = 0.22$ ) matrices.






59

60 **Extended Data Figure 7. Model predicts cell volume increase and sphericity decrease with stiffness in**  
 61 **viscoelastic matrices. a-b,** Quantification from the simulations of the volume (a) and sphericity (b) of the  
 62 spheroids, respectively, over time for soft, intermediate and stiff elastic and viscoelastic matrices. The  
 63 dimensionless parameter in the model for stiff elastic ( $A = \frac{\tau_a}{\tau_m} = 0.4, \mu = \frac{\mu_t}{\mu_m} = 0.002, j = \frac{\tau_g}{\tau_t} = 0.05$ );  
 64 intermediate elastic ( $A = \frac{\tau_a}{\tau_m} = 0.13, \mu = \frac{\mu_t}{\mu_m} = 0.002, j = \frac{\tau_g}{\tau_t} = 0.05$ ); soft elastic ( $A = \frac{\tau_a}{\tau_m} =$   
 65  $0.003, \mu = \frac{\mu_t}{\mu_m} = 0.002, j = \frac{\tau_g}{\tau_t} = 0.04$ ); stiff viscoelastic ( $A = \frac{\tau_a}{\tau_m} = 400, \mu = \frac{\mu_t}{\mu_m} = 2, j = \frac{\tau_g}{\tau_t} = 0.22$ );  
 66 intermediate viscoelastic ( $A = \frac{\tau_a}{\tau_m} = 133, \mu = \frac{\mu_t}{\mu_m} = 2, j = \frac{\tau_g}{\tau_t} = 0.16$ ); and soft viscoelastic  
 67 ( $A = \frac{\tau_a}{\tau_m} = 3.3, \mu = \frac{\mu_t}{\mu_m} = 2, j = \frac{\tau_g}{\tau_t} = 0.14$ ) matrices.



68

69 **Extended Data Figure 8. Quantification of hydrogel mechanical properties.** **a**, Quantification of the  
 70 storage modulus of alginate hydrogels. n=8,4,5,7,9,5 gels per condition. **c**, Quantification of the timescale  
 71 at which an initially applied stress is relaxed to half its original value. n=13,14,19,16,16,19 gels per  
 72 condition.



73

74 **Extended Data Figure 9. Inhibition of cell motility prevents morphological instability, independent of**

75 **gel stiffness. a,** The influence of eliminating cell motility, in gels with varying stiffness, was simulated in

76 the model. **b,** Images of spheroids, from final timepoint of simulation, in increasingly stiff viscoelastic

77 gels in control case (upper row) and when cell motility was suppressed (lower row). **c-d,** Simulation

78 prediction of projected area (**c**) and circularity (**d**) evolution over time of spheroids in increasingly stiff

79 viscoelastic and elastic gels when cell motility was suppressed (lower row). The dimensionless

80 parameter in the model for stiff elastic ( $A = \frac{\tau_a}{\tau_m} = 0.03, \mu = \frac{\mu_t}{\mu_m} = 0.002, j = \frac{\tau_g}{\tau_t} \sim 0$ ); intermediate

81 elastic ( $A = \frac{\tau_a}{\tau_m} = 0.017, \mu = \frac{\mu_t}{\mu_m} = 0.002, j = \frac{\tau_g}{\tau_t} \sim 0$ ); soft elastic ( $A = \frac{\tau_a}{\tau_m} = 0.0017, \mu = \frac{\mu_t}{\mu_m} =$

82  $0.002, j = \frac{\tau_g}{\tau_t} \sim 0$ ); stiff viscoelastic ( $A = \frac{\tau_a}{\tau_m} = 33.3, \mu = \frac{\mu_t}{\mu_m} = 2, j = \frac{\tau_g}{\tau_t} \sim 0$ ); intermediate viscoelastic


83 ( $A = \frac{\tau_a}{\tau_m} = 16.7, \mu = \frac{\mu_t}{\mu_m} = 2, j = \frac{\tau_g}{\tau_t} \sim 0$ ); and soft viscoelastic ( $A = \frac{\tau_a}{\tau_m} = 1.7, \mu = \frac{\mu_t}{\mu_m} = 2, j = \frac{\tau_g}{\tau_t} \sim 0$ )

84 matrices. **e,** Quantification of spheroids circularity after 5 days in soft and stiff viscoelastic matrices with

85 Arp2/3 (CK666) and Rac1 (NSC23766) inhibitors. n=24,21,21,24,25,22,27,21 spheroids per condition.

86 Statistical analysis was performed using Kruskal–Wallis test followed by post hoc Dunn’s test. All data


87 represent mean  $\pm$  s.d.



89

90 **Extended Data Figure 10. Inhibition of cell proliferation prevents morphological instability**


91 **independently of the gel stiffness.** **a**, the influence of eliminating cell proliferation, in gels of increasing  
 92 stiffness, was simulated in the model. **b**, Images of spheroids, from final timepoint of simulation, in  
 93 increasingly stiff viscoelastic gels in control case (upper row) and when cell proliferation was inhibited. **c**-  
 94 **d**, Simulation prediction of projected area (**c**) and circularity (**d**) evolution over time of spheroids in  
 95 increasingly stiff elastic and viscoelastic gels when cell proliferation was suppressed. The dimensionless  
 96 parameter in the model for stiff elastic ( $A = \frac{\tau_a}{\tau_m} = 0.4, \mu = \frac{\mu_t}{\mu_m} = 0.002, j = \frac{\tau_g}{\tau_t} = 0$ ); inter elastic  
 97 ( $A = \frac{\tau_a}{\tau_m} = 0.13, \mu = \frac{\mu_t}{\mu_m} = 0.002, j = \frac{\tau_g}{\tau_t} = 0$ ); soft elastic ( $A = \frac{\tau_a}{\tau_m} = 0.003, \mu = \frac{\mu_t}{\mu_m} = 0.002, j = \frac{\tau_g}{\tau_t} =$   
 98  $0$ ); stiff viscoelastic ( $A = \frac{\tau_a}{\tau_m} = 400, \mu = \frac{\mu_t}{\mu_m} = 2, j = \frac{\tau_g}{\tau_t} = 0$ ); inter viscoelastic ( $A = \frac{\tau_a}{\tau_m} = 133.3, \mu =$   
 99  $\frac{\mu_t}{\mu_m} = 2, j = \frac{\tau_g}{\tau_t} = 0$ ); and soft viscoelastic ( $A = \frac{\tau_a}{\tau_m} = 3.33, \mu = \frac{\mu_t}{\mu_m} = 2, j = \frac{\tau_g}{\tau_t} = 0$ ) matrices.




100

101 **Extended Data Figure 11. Development of a microfluidic device to study the influence of pressure in**  
 102 **tissue morphological stability.** **a**, Pillars are distributed across the petri dish and an unpolymerized  
 103 alginate solution is loaded. **b**, A PDMS slab is placed on top of the pillars and alginate is allowed to  
 104 polymerize for 45 min. **c**, cells are loaded at a constant rate ( $1\mu\text{l}/\text{min}$ ) with a syringe pump through a hole  
 105 in the PDMS slab. Due to the pressure ( $\sim 5\text{ kPa}$ ), cells displace the material. **d**, Model prediction for cell  
 106 flux driven experiments for elastic ( $A = \frac{\tau_a}{\tau_m} = 0.003, \mu = \frac{\mu_t}{\mu_m} = 0.002, j = \frac{\tau_g}{\tau_t} = 5$ ) and viscoelastic  
 107 ( $A = \frac{\tau_a}{\tau_m} = 3.33, \mu = \frac{\mu_t}{\mu_m} = 2, j = \frac{\tau_g}{\tau_t} = 5$ ) matrices. **e**, Examples of Hoechst staining of cells in elastic and  
 108 viscoelastic matrices. Scale bar is  $400\ \mu\text{m}$ . **f**, Detail of the leading front of tissues in viscoelastic and elastic  
 109 matrices in these experiments. Scale bar is  $200\ \mu\text{m}$ . **g**, Quantification of the circularity in elastic and  
 110 viscoelastic hydrogels.  $n=6,7$  experiments per condition. Statistical analysis was performed using Mann-  
 111 Whitney U-test.

a




b




112

113 **Extended Data Figure 12. a, 3D model for cell flux driven simulations.** The texts in light blue/light red  
 114 color boxes describe the matrix/cell property and interactions therein. The yellow boxes represent the  
 115 parameters which we vary to probe the phase space of morphologies. The cells are being injected at the  
 116 center of the tissue to mimic the experiments and hence the proliferation is independent of the stress.  
 117 Now motility is not a function of stiffness and its value has been chosen to be very small. **b,**  
 118 Quantification from the simulations of the circularity of the spheroids.


a



b



c




119

120 **Extended Data Figure 13. Phase diagram simulations.** a, 3D phase diagram including the results of  
 121 multiple simulation runs utilized to determine the phase boundaries. Each dot represents the final result  
 122 of a single simulation run under specific condition, and they are color coded (blue= stable tissue growth;  
 123 red=unstable tissue growth). b, A two-dimensional phase diagram for low motility case as a consequence  
 124 of slow addition of cells, always leading to a stable spheroid (all blue). c, Two-dimensional phase diagram  
 125 for the controlled cell-flux driven case where the addition of cells is fast. This leads to an inverted behavior,


126 the growth of tissue in elastic matrix (close to origin) is branched (red) and in viscoelastic matrix (away  
 127 from origin) is a stable (blue). In b and c, the red and blue dots against represent data points extracted  
 128 from individual simulations. When the scaled proliferation pressure  $j = \frac{\tau_g}{\tau_t} \ll 1$ , the tissue grows as a  
 129 stable spheroid (Fig. 2i,j and Extended Data Fig. 9, 10, 13b). In contrast, when the scaled matrix relaxation  
 130 time  $A = \frac{\tau_a}{\tau_m} \ll 1$ , the tissue remains spheroidal and is morphologically stable as long as the scaled  
 131 proliferation pressure  $j = \frac{\tau_g}{\tau_t} \sim O(1)$  (top panel of Fig.1d and Fig 2b). In contrast, when the scaled matrix  
 132 relaxation time  $A = \frac{\tau_a}{\tau_m} \gg 1$ : if the scaled proliferation pressure  $j = \frac{\tau_g}{\tau_t} \ll 1$ , the tissue grows as a stable  
 133 spheroid (bottom right of Fig. 2i and bottom panel of Extended Data Fig. 11b); if the scaled proliferation  
 134 pressure  $j = \frac{\tau_g}{\tau_t} \sim O(1)$ , the growth is unstable and the tissue breaks symmetry and develops branches  
 135 (bottom panel of Fig.1d and bottom panel of Fig. 2b and 3b); if the scaled proliferation pressure  $j = \frac{\tau_g}{\tau_t} \gg$   
 136 1, the morphological stability of the tissue depends on  $\mu = \frac{\mu_t}{\mu_m}$  (see Extended Data Fig11d,e and 13c); for  
 137  $\mu = \frac{\mu_t}{\mu_m} \ll 1$ , the tissue remains spheroidal (Extended Data Fig.11d,e, 13c); for  $\mu = \frac{\mu_t}{\mu_m} \gg 1$ , growth is  
 138 unstable and the tissue breaks symmetry and develops branches (Extended Data Fig.11d,e, 13c).





140

141 **Extended Data Figure 14. Organoids grow, break symmetry and form buds with time.** **a**, Examples of  
 142 growth of intestinal organoids in elastic versus viscoelastic hydrogels over 7 days. Phalloidin in cyan,  
 143 Hoechst in magenta. Scale bar is 100 $\mu$ m. **b**, Quantification of organoid circularity in different stiffness  
 144 elastic and viscoelastic hydrogels.  $n=32,32,38,37$  organoids per condition. Statistical analysis was  
 145 performed using Kruskal–Wallis test followed by post hoc Dunn’s test. Data represent mean  $\pm$  s.d.



146

147 **Extended Data Figure 15. Organoids grow, develop and pattern similarly in the presence of ouabain. a,**  
 148 Quantification of the percentage of cells which form colonies in gels after 7 days with or without  
 149 ouabain. **b-d**, Representative examples (**b**) and quantification of organoids area (**c**) and circularity (**d**)  
 150 after 7 days with or without ouabain in the culture medium.  $n=22,17,32,27$  **b,c** /  $20,14,24,20$  **d**  
 151 organoids per condition. Statistical analysis was performed using Kruskal–Wallis test followed by post  
 152 hoc Dunn’s test. **e**, Representative examples of Lysozyme, Hoechst and phalloidin stainings of organoids  
 153 with ouabain. Lysozyme (magenta) and Hoechst (cyan) in the left and phalloidin (cyan) in the right.  
 154 Higher magnification images are provided on bottom row. All data represent mean  $\pm$  s.d., all scale bars  
 155 are 100  $\mu\text{m}$ .

- 156 Video S1: Examples of spheroids growth in elastic (left) and viscoelastic (right) matrices.
- 157 Video S2: Examples of simulated tissue growth in elastic (left) and viscoelastic (right) matrices.
- 158 Video S3: Examples of simulated tissue growth when cell motility is inhibited in elastic (left) and  
159 viscoelastic(right) matrices.
- 160 Video S4: Examples of simulated tissue growth when cell proliferation is inhibited in elastic (left) and  
161 viscoelastic(right) matrices.
- 162 Video S5: Examples of simulated tissue growth in elastic (upper row) and viscoelastic (lower row) in  
163 matrices of increasing stiffness.
- 164 Video S6: Examples of simulated tissue growth when cell migration is inhibited in elastic (upper row) and  
165 viscoelastic (lower row) in matrices of increasing stiffness.
- 166 Video S7: Examples of simulated tissue growth when cell proliferation is inhibited in elastic (upper row)  
167 and viscoelastic (lower row) in matrices of increasing stiffness.
- 168 Video S8: Examples of simulated tissue growth when cells are continuously added to the tissue in elastic  
169 (left) and viscoelastic (right) matrices.

170 **Materials and methods**

171 **Alginate hydrogel preparation.**

172 Sodium alginate with an average molecular weight of 138 kDa (high molecular weight) was purchased  
173 from FMC Biopolymer and used to prepare more elastic and viscoelastic gels as described previously<sup>1,2</sup>.  
174 Briefly, alginate was irradiated with a 5mRad cobalt source to obtain a low molecular weight alginate (38  
175 kDa). The adhesion peptide GGGGRGDSP (RGD – Peptide 2.0) was covalently coupled to alginate (RGD  
176 concentration 2.7mM) utilizing carbodiimide chemistry (Sulfo-NHS, Pierce Chemical; EDC, Sigma-Aldrich).  
177 Next, modified alginate was dialyzed against deionized water for 3-4 days (molecular weight cutoff of  
178 3.5kDa), treated with activated charcoal (Sigma-Aldrich), filter sterilized (0.22µm) and lyophilized for one  
179 week. The day before the experiment, alginate was reconstituted in DMEM/F12 (Dulbecco's Modified  
180 Eagle Medium: Nutrient Mixture F-12, Gibco). For the MCF10A spheroids experiments, two syringes per  
181 gel were prepared to get a 2% alginate gel. One containing 2.5% alginate. The second syringe contained  
182 normal medium and different amounts of calcium sulfate depending on the material mechanical  
183 properties. Calcium sulfate was previously diluted in media without supplements. Then, spheroids were  
184 gently added to the syringe with media and the syringe was turned up and down to mix well the calcium  
185 sulfate. Next, both syringes were connected together with a female-female Luer-lock coupler, taking care  
186 not to introduce bubbles or air into the mixture. After, the two solutions were mixed rapidly and  
187 immediately deposited the alginate gel on top of a plate. The recipes for all alginate hydrogels were the  
188 same except the calcium sulphate concentration that increased to increase the stiffness: 16.8, 28.8, 57.6  
189 mM and 33.6, 52.8, 96 mM for elastic and viscoelastic hydrogels respectively. For intestinal organoids  
190 experiments, gels were prepared differently. First, the alginate and Matrigel solution was prepared.  
191 Alginate and Matrigel were left on ice for over an hour. Next, Matrigel was added to a 2.5% alginate  
192 solution. As Matrigel concentration varies from batch to batch, the appropriate amount of media (with  
193 no supplements) was added to a final concentration of 1.25% alginate and 5mg/ml Matrigel. This solution

194 was thoroughly mixed for 40-50 times with a pipette, being careful not to generate bubbles and  
195 maintained in ice. First, a syringe with alginate + Matrigel solution was prepared and left on top of the ice.  
196 A second syringe was prepared with medium and the appropriate concentration of calcium sulphate. In  
197 parallel, Matrigel with organoids was dissolved with cell recovery solution. The recipes for all alginate-  
198 matrigel hydrogels were the same except the calcium sulphate concentration that increased to increase  
199 the stiffness: 26.4, 48 mM and 48, 96 mM for elastic and viscoelastic hydrogels respectively.

#### 200 **Mechanical characterization of hydrogels.**

201 The storage moduli of hydrogels were determined with an AR-G2 stress-controlled rheometer (TA  
202 instruments) as utilized previously<sup>2,3</sup>. Briefly, a 20 mm parallel plate was used with a gap of 1mm. The  
203 circular plate was immediately placed on the polymer solution before the hydrogel started to gel, forming  
204 a 20 mm disk hydrogel. Oscillatory rheology (1Hz, 1% strain) was used to measure the storage modulus.  
205 Gels were maintained at 37°C until equilibrium was reached.

206 To measure the stress relaxation half time a compression test with an Instron 3342 mechanical apparatus  
207 (Norwick, MA) was performed as described previously<sup>2,4</sup>. Briefly, hydrogels were fabricated with a 2mm  
208 height, and allowed to equilibrate for 24h<sup>3,5,6</sup>. Then, gels were strained at a 1mm/min rate until a 15%  
209 strain was reached; the strain was then held constant. The stress relaxation half time was measured as  
210 the time at which the initial stress decreased by a factor of 2.

#### 211 **MCF10A cell culture**

212 MCF10A breast cell line (ATCC) were cultured following the protocols developed by Debnath and Brugge<sup>7</sup>.  
213 Briefly, cells were cultured in DMEM/F12 media (Gicbo) supplemented with 5% Horse Serum (Invitrogen),  
214 1% Pen/Strep (Invitrogen), 20ng/ml EGF (Peprotech), 0.5 mg/ml Hydrocortisone (Sigma-Aldrich), 100  
215 ng/ml Cholera toxin (Sigma-Aldrich) and 10µg/ml Insulin (Sigma-Aldrich).

## 216 **MCF10A spheroids experiments**

217 To prepare MCF10A spheroids, cells were trypsinized from tissue culture flasks and resuspended in  
218 pretreated Aggrewell multi-well plates (Aggrewell 400) to generate spheroids of ~2000 cells. Plates were  
219 left overnight in the incubator to allow spheroids to form. The spheroids were then carefully removed  
220 from the Aggrewell plates and added to the polymer solution before gelation (see hydrogel preparation  
221 above). A plate was deposited on top of each gel to provide a final controlled height of 1mm, and gels  
222 were left in the incubator for 45min. Individual gel samples were then obtained with an 8mm puncher,  
223 and each gel was introduced into a separate well of a 24-well plate. The media was changed after 2 hr,  
224 and during experiments the media was changed every 2 days, except where indicated. For experiments  
225 with inhibitors, once spheroids were encapsulated in gels and gels equilibrated, media with the defined  
226 inhibitor concentration was added. The media with inhibitors was also changed every 2 days. The  
227 inhibitors used were: 10 $\mu$ M Y27632 (SIGMA-ALDRICH) to inhibit ROCK, 50 $\mu$ M NSC23766 (TOCRIS) to  
228 inhibit Rac1, 100 $\mu$ M CK666 to inhibit ARP 2/3, 10 $\mu$ M Gadolinium to block ion channels, 5 $\mu$ M PF 573228  
229 (TOCRIS) to inhibit FAK, 2mM Thymidine (SIGMA-ALDRICH) to block cell cycle progression.

## 230 **Intestinal organoids culture.**

231 Intestinal organoids were cultured from isolated jejunal crypts of Lgr5<sup>CreERGFP</sup> adult mice (Jackson  
232 Laboratory) in which the Lgr5<sup>+</sup> stem cells are labeled with GFP expression. Intestinal organoids were  
233 cultured in DMEM/F12 media (Invitrogen) supplemented with 10% RS2 condition medium (RS2 producer  
234 line is a gift from Dr. Xi He, Boston Children's Hospital), 10mM HEPES (ThermoFisher), 1X GlutaMAX<sup>TM</sup>  
235 supplement (ThermoFisher), 1X N2 supplement (ThermoFisher), 1X B27 supplement (ThermoFisher), 10  
236  $\mu$ M DMH1 (Cayman), 20  $\mu$ M CHIR99021 (LC Laboratories), 50 ng/ml EGF (R&D), 10  $\mu$ M Y27632 (LC  
237 Laboratories) and 0.1 mg/ml Primocin (invivoGen). For routine culture, medium was changed every 2-3  
238 days and organoids were passaged after 5 days at the latest. To passage the organoids, cell recovery

239 solution (CORNING) was added to the wells containing intestinal organoids in Matrigel (CORNING) to  
240 disrupt matrigel. After adding the Cell Recovery Solution, the plate was left on ice until Matrigel was  
241 degraded. Then, organoids were gently disrupted using mechanical agitation. Disrupted organoids were  
242 added to a Matrigel containing solution and 30  $\mu$ l droplets of Matrigel with organoids were deposited in  
243 pre-heated wells. These wells were left in an incubator for 30 min to allow Matrigel to solidify and before  
244 adding medium.

#### 245 **Intestinal organoids experiments.**

246 Intestinal organoid encapsulation was similar to the procedure utilized for MCF10A spheroids, although  
247 in this case an IPN of alginate and Matrigel was used for encapsulation. Intestinal organoids were first  
248 cultured in Matrigel (BD Biosciences) for 1-2 weeks. Then, the Matrigel was dissolved with cell recovery  
249 solution (Corning) and organoids were dissociated with TrypLE (Gibco). After dissociation, cells were  
250 encapsulated in Matrigel for 24h. This process allows the size of organoids to be more homogeneous at  
251 the start of the experiment. After 24h, organoids were added to the syringe with Matrigel + alginate prior  
252 to gel formation. To control the thickness of the gels, a plate was deposited on top of each gel at a  
253 controlled height of 1mm. Gels were allowed to form inside the incubators for 45min, and individual gel  
254 samples were then punched with an 8mm puncher. Each gel was introduced into a separate well of a 24-  
255 well plate. Medium was changed after two hours, and subsequently every 2 days, except where indicated.  
256 For experiments with addition of 100  $\mu$ M Ouabain (Sigma-Aldrich), media with ouabain was added after  
257 equilibration and was changed every day.

#### 258 **Bulk hydrogel immunostaining**

259 Hydrogels were fixed with 4% paraformaldehyde for 30 min. After fixation, hydrogels were washed with  
260 PBS with 10mM EDTA to facilitate staining. Then, cells within hydrogels were permeabilized and blocked  
261 with 0.5% triton, 3% Goat serum in PBS with calcium (blocking buffer) for 24h. Once hydrogels were

262 permeabilized and blocked, primary antibodies were added in blocking buffer for 24h. Primary antibodies  
263 used were YAP (Santa Cruz, 1:200), Cytokeratin 14 (Covance, 1:100), Vimentin (abcam, 1:200). After  
264 incubation with primary antibodies, Hydrogels were washed for 24h in blocking buffer. Next, secondary  
265 antibodies were added in blocking buffer. Then, hydrogels were washed for 3h and blocking buffer with  
266 phalloidin (ThermoFisher, 1:200) was then added for 24h to label F-actin. Hydrogels were then washed  
267 for 8 hours with blocking buffer with Hoechst (ThermoFisher, 1:2000) to label cell nuclei and, afterwards,  
268 washed with PBS overnight. Finally, Prolong (ThermoFisher) antifade reagent was added to the hydrogels.

### 269 **Immunostaining of hydrogel sections**

270 Hydrogels were fixed with 4% paraformaldehyde for 30 min. After fixation, hydrogels were washed 3 times  
271 with PBS containing calcium (cPBS), and then incubated overnight in cPBS containing 30% Sucrose.  
272 Hydrogels were then incubated in a solution consisting of equal volumes of a 30% Sucrose in cPBS  
273 containing solution, and OCT (Tissue-Tek) solution for 24h. Next, the solution was removed and hydrogels  
274 were embedded in OCT for several hours, and then frozen. The frozen hydrogels were sectioned with a  
275 cryostat (Leica CM1950) to a thickness of 15  $\mu\text{m}$ . Sections were permeabilized with a PBS solution  
276 containing 0.2% triton and 3% Goat Serum. Next, pFAK (abcam,1:100) antibody was added for 3h. Then,  
277 after 6 washes, a secondary antibody with phalloidin was added for an hour. Last, ProLong (ThermoFisher)  
278 antifade reagent was added. After mounting, sections were imaged with 20x (NA=0.8), 40x (NA=1.0) or  
279 63x (NA=1.4) water immersion objectives in an Upright laser-scanning confocal Zeiss LSM 710.

### 280 **Bulk Organoid staining:**

281 To follow the 3D structure and evolution of organoids, the F-actin and nuclei were stained with Phalloidin  
282 and Hoechst respectively. Hydrogels were fixed with 4% paraformaldehyde for 30 min. After fixation,  
283 hydrogels were washed with PBS containing 10mM EDTA to facilitate staining. Then, hydrogels were  
284 permeabilized and blocked with 0.5% triton, 3% Goat serum in PBS with calcium (blocking buffer) for 48h.



285 Once hydrogels were permeabilized and blocked, phalloidin (ThermoFisher, 1:200) was added to blocking  
286 buffer to label F-actin and incubated with gels for 24h. Hydrogels were then washed for 8 hours with  
287 blocking buffer with Hoechst (ThermoFisher, 1:2000) to label the nuclei, and then washed with PBS  
288 overnight. Finally, Prolong (ThermoFisher) antifade reagent was added to the hydrogels. After mounting,  
289 organoids were imaged with a 40x (NA=1.0) water immersion objective in an Upright laser-scanning  
290 confocal Zeiss LSM 710.

### 291 **Organoid immunostaining:**

292 Hydrogels were incubated in cell recovery solution (CORNING) for 45 min on ice. The alginate in the gels  
293 was then degraded with 34 U/ml alginate lyase (Sigma-Aldrich), while maintaining gels on ice. Hydrogels  
294 were subsequently fixed with 4% paraformaldehyde for 30 min. After fixation, organoids were  
295 permeabilized for 30 min with 0.5% Triton. Once organoids were permeabilized, they were blocked with  
296 3% Goat serum, 0.1% Triton in PBS for 3h. Then, primary antibody (Lysozyme, Dako, 1:200) was added in  
297 3% Goat Serum, 0,1% Triton in PBS and left overnight at 4 degrees. Once the primary antibody was washed  
298 the next day, secondary antibodies (ThermoFisher, 1:200) and phalloidin (1:200) were added to gels in a  
299 solution containing 3% Goat Serum, 0,1% Triton in PBS for 4h. Secondary antibodies were then washed,  
300 organoids incubated with Hoechst (ThermoFisher, 1:2000) for 4h, washed 6 times and, last, ProLong  
301 (ThermoFisher) was added. After mounting, organoids were imaged with a 40x (NA=1.0) water immersion  
302 objective in a laser-scanning confocal Upright Zeiss LSM 710.

### 303 **Analysis of cell proliferation in tissues**

304 In experiments with MCF10A spheroids, EdU (Click-iT™ EdU Cell Proliferation Kit, Invitrogen) was added  
305 for 4 hr to spheroids containing bulk hydrogels at day 5. For intestinal organoids experiments, EdU was  
306 added for 2h at day 7. After following the staining protocol provided by Invitrogen, ProLong mounting  
307 media was added. After mounting, spheroids or organoids were imaged with a 20x (NA=0.8) or 40x

308 (NA=1.0) water immersion objectives in an Upright laser-scanning confocal Zeiss LSM 710. The percentage  
309 of EdU positive cells was quantified by determining the total number of cells from the Hoechst channel,  
310 and then the number of EdU positive nuclei. Custom MATLAB software was used to quantify the spatial  
311 distribution of EdU positive cells and cell density across the spheroids. In brief, the perimeter of a 2D slice  
312 of a spheroid was first defined. Then, the tissue area was divided into squares of defined area. To measure  
313 the local density and the percentage of EdU positive cells, the software measures the number of nuclei  
314 from the Hoechst staining and the number of EdU positive nuclei per square. With these measurements,  
315 the local density of cells and the percentage of EdU positive cells are calculated. The radial distribution of  
316 cell density and percentage of EdU positive cells was also quantified. To accomplish, the distance from the  
317 center to the edge of the tissue was normalized in order to compare all spheroids and conditions.

#### 318 **Spheroid area and circularity quantification**

319 To measure spheroids or organoids circularity and area during experiments, phase contrast images were  
320 taken with a 4x and 10x objective with a Microscope (EVOS) every day or the last day of experiments.  
321 These images were quantified with Image J. Briefly, the perimeter of each individual spheroid/organoid  
322 was drawn manually, and the enclosed area and circularity was measured.

#### 323 **Cytokeratin 14 quantification**

324 To measure cytokeratin 14 staining intensity, images were obtained after immunostaining with a 20x  
325 (NA=0.8) or 40x (NA=1.0) water immersion objective in an Upright laser-scanning confocal Zeiss LSM 710.  
326 Then, custom MATLAB software was used to quantify the average intensity of the cytokeratin 14 staining  
327 per spheroid. First, the perimeter of each spheroid was defined. Then, the perimeter ring width was  
328 widened inwards and outwards to include all pixels positive for cytokeratin 14 staining. The average  
329 cytokeratin 14 intensity was then determined, and all values were normalized to the average value of  
330 cytokeratin 14 staining in elastic hydrogels.

### 331 **YAP quantification**

332 To quantify YAP staining, images of immunostained spheroids were taken with a 100X (NA=1.40) oil  
333 immersion objective using a laser-scanning confocal Upright Zeiss LSM 710. The percentage of cells with  
334 nuclear YAP was quantified by counting the number of cells with nuclear YAP with respect to the total  
335 number of cells. These measurements were performed in the core of spheroids, the edges, and cells  
336 present at the initiation of branches (in viscoelastic gels).

### 337 **Mice experiments**

338 Female, 3-week-old NOD SCID mice (NOD.Cg-Prkdc<sup>scid</sup>/J) were purchased from Jackson Laboratory (Bar  
339 Harbor, ME, USA). MDA-MB-231 cells ( $1 \times 10^7$  cells/mL) were added to alginate solutions (hydrogel  
340 preparation as noted above to yield the stiff viscoelastic and elastic gels), mixed and immediately injected  
341 subcutaneously at the left flank to allow gelation in situ. The dimensions of the growing tumors were  
342 measured externally using calipers, and the volume of an ellipsoid was calculated. All animal studies were  
343 performed in accordance with guidelines set by the National Institutes of Health and Harvard University  
344 Faculty of Arts and Sciences' Institutional Animal Care and Use Committee (IACUC).

### 345 **Microfluidic device development and cell flux driven experiments**

346 To explore the impact of pressure on tissue growth, gels containing cell spheroids were confined by  
347 placing a polydimethylsiloxane (PDMS) cover over gels contained within a petri dish. The PDMS cover was  
348 fabricated to allow continuous injection of a cell suspension into the center of a spheroid to model  
349 pressure-drive tissue growth. The cover was fabricated by mixing PDMS (Sylgard 184, Dow Corning,  
350 Midland, MI) base and cross-linker in a 5:1 weight ratio using a Thinky mixer (AR-100, Thinky Corp., Tokyo,  
351 Japan). The PDMS was degassed for 20 minutes and the mold was cured in the oven at 65C overnight. The  
352 device was then cut out of the mold and a hole through the device was created with a 1.2mm biopsy  
353 punch (Uni-Core, GE Healthcare Life Sciences, Pittsburgh, PA). The PDMS cover was then surfaced treated

354 with Aquapel (PPG Industries, Pittsburgh, PA) to make the gel-contacting surface hydrophobic. Once  
 355 ready, hydrogel prepared as described above is poured onto a petri dish 100mm to allow gelation. Eight  
 356 circular pillars were used to surround the forming hydrogel to control its thickness. The PDMS cover was  
 357 then placed on top of the forming gel, supported by the pillars, to create gels  $\sim 170\mu\text{m}$  thick. Hydrogels  
 358 were allowed to cure at room temperature for 30 minutes. During this time, cells are stained (Hoechst  
 359 nucleus stain -Thermo-Fisher-), suspended in cell medium at a density of  $1 \times 10^7$  cells/ml, and are loaded  
 360 into a syringe. Once the hydrogel has formed, the syringe pump was used to inject the cell suspension  
 361 into the center of the gel using a tubing of diameter 0.4mm inserted through the hole created in the PDMS  
 362 cover. Cells were injected for 9 minutes, at a flow rate of  $1\mu\text{l}/\text{min}$ , to provide a constant pressure of  $\sim 5$   
 363 kPa.

#### 364 **Theoretical model**

365 In our experiments, a tissue comprised of motile, proliferating cells is initially encapsulated in a viscoelastic  
 366 gel. Both the passive matrix and active cells are modeled using interacting soft spherical particles of size  
 367  $a$  subject to forces with appropriate Langevin dynamics. Initially, a collection of motile proliferating cells  
 368 is surrounded by a passive set of particles representing the extracellular matrix. Cells are assumed to be  
 369 active with a random movement analogous to a Brownian particle, but this movement is not related to  
 370 temperature of the environment and is instead due to the active nature of the cell<sup>8,9</sup>. The cells also repel  
 371 each other with a short-range force and also repel the matrix to avoid the overlap. The equation of motion  
 372 for a cell with coordinate  $\mathbf{r}_i^t$  is:

$$373 \quad \mu_t \dot{\mathbf{r}}_i^t = -\frac{\partial U^t}{\partial \mathbf{r}_i^t} + \boldsymbol{\xi}_i(t)$$

374 where  $\mu_t$  is the tissue viscous friction,  $U^t$  is the interaction potential for the cells, and  $\boldsymbol{\xi}(t)$  is random force  
 375 with zero mean and a variance related to its activity, i.e.  $\langle \boldsymbol{\xi}(t) \rangle = 0$ ;  $\langle \xi_{i,\alpha}(t) \xi_{i,\beta}(t') \rangle =$

376  $2 M\mu_t\delta(t - t')\delta_{\alpha\beta}$ . The viscous friction is a result of the interaction of cells with the extra-cellular matrix  
 377 (ECM). Assumed that the inertial effects are negligible and hence considered an overdamped motion. The  
 378 interaction potential for the cells,  $U^t$  has two contributions:

$$379 \quad U^t(\mathbf{x}) = \frac{1}{2}\sum_j\sum_{i\neq j}u_{ij}^t + \frac{1}{2}\sum_k\sum_i u_{ik}^{tm},$$

380 the first one is the interaction between the cells themselves, which we consider having short-range  
 381 repulsion to avoid the overlap and mid-range (two cell size) attraction, and no long-range (greater than  
 382 two cell size) interaction<sup>10</sup> :

$$383 \quad u_{ij}^t = \begin{cases} \epsilon \left( \left( \frac{a}{r_{ij}} \right)^2 - 1 \right) \left( \left( \frac{r_c}{r_{ij}} \right)^2 - 1 \right)^2 & \text{for } r_{ij} \leq r_c, \\ 0 & \text{for } r_{ij} > r_c \end{cases}$$

384 where  $r_c = 2a$ ; the second one we assume that there is repulsive interaction between the cell and  
 385 matrix of diameter 'a' to avoid the overlap and that to be harmonic:

$$386 \quad u_{ik}^{tm} = \begin{cases} k_{tm} (r_{ik} - a)^2 & \text{for } r_{ik} < a \\ 0 & \text{for } r_{ik} \geq a \end{cases}$$

387 where  $r_{ij} = |\mathbf{r}_j^t - \mathbf{r}_i^t|$  is the distance between the cell 'i' and 'j' and  $r_{ik} = |\mathbf{r}_k^m - \mathbf{r}_i^t|$  is the distance  
 388 between the cell 'i' and matrix bead 'k'. The random force  $\xi_i(t)$  is assumed to be zero-mean and uniformly  
 389 distributed so that:

$$390 \quad \langle \xi_{i,\alpha}(t) \rangle = 0,$$

$$391 \quad \langle \xi_{i,\alpha}(t)\xi_{i,\beta}(t') \rangle = 2 M\mu_t\delta(t - t')\delta_{\alpha\beta},$$

392 where is the single cell activity/motility and  $\xi_{i,\alpha}$  is the x or y or z component of  $\xi_i$ . By using the result  
 393 from statistical physics<sup>11</sup>, we can relate the microscopic diffusivity of a (Brownian) cell to the activity by

$$394 \quad \text{the relation } D = \frac{M}{\mu_t}.$$

395

396 In the model, the cell division has two constraints, a cell can divide only if it is older than a free growth-  
397 rate time scale  $\tau_g$ , and a cell-division will be acceptable only if it is energetically favorable<sup>12,13</sup>. To decide  
398 the energetically favorable divisions, we are using a Metropolis-Hastings algorithm, a Markov chain Monte  
399 Carlo method<sup>14</sup>. At each time step we randomly pick a cell and check for the age of the cell, if the cell is  
400 older than  $\tau_g$ , it is allowed to divide, the new cell will take space next to the old cell, with an angle which  
401 is chosen from a uniform random distribution over  $[0 - 2\pi]$ . We calculate the cost of energy  $\Delta E = E_f -$   
402  $E_o$  to displace the cell and matrix, where  $E_{f/o}$  is the total energy of the cell aggregate and matrix  
403 after/before cell division. Then we accept this cell division with the probability:

$$P = \begin{cases} \exp\left(-\frac{\Delta E}{M}\right) & \text{for } \Delta E \geq 0 \\ 1 & \text{for } \Delta E < 0 \end{cases}.$$

404

405 To model the matrix phase, we assume that the matrix is made of mono-disperse spherical bead of the  
406 same size as the cell 'a'. These beads are passive in nature and they get displaced as a reaction to tissue  
407 activity and pressure applied by the tissue proliferation. The bead moves under the influence of three  
408 forces: (i) the first arises from the elastic nature of the matrix with elasticity coefficient  $G'$ ; the second  
409 arises from the interaction between the beads themselves, similar to what we have for the cell-cell  
410 interaction; and the last arises from the repulsion between the bead and the tissue to avoid the overlap.  
411 The equation of motion for a bead with coordinate  $\mathbf{r}_i^m$  is:

412

$$\mu_m \dot{\mathbf{r}}_i^m = -\frac{\partial U^m}{\partial \mathbf{r}_i^m}$$

413 where  $\mu_m$  is the matrix viscous friction,  $U^m$  is the interaction potential for the matrix. Similar to the cell  
 414 dynamics, we have assumed that the inertial effects are negligible and hence considered an overdamped  
 415 motion. The interaction potential for the matrix  $U^m$  has three contributions:

$$416 \quad U^m(\mathbf{x}) = \frac{1}{2} \sum_i u_i^E + \frac{1}{2} \sum_j \sum_{i \neq j} u_{ij}^m + \frac{1}{2} \sum_k \sum_i u_{ik}^{tm},$$

417 the first term is the elastic interaction for individual beads, we consider that each bead ' $i$ ' is attached to  
 418 its initial position  $\mathbf{r}_i^{m-0}$  and if the bead gets displaced from its initial position to a new position  $\mathbf{r}_i^m$ , due  
 419 to the elastic nature bead tries to go back to its initial position. We assume the interaction to be:

$$420 \quad u_i^E = G'(\mathbf{r}_i^m - \mathbf{r}_i^{m-0})^2;$$

421 where  $G'$  is the elasticity coefficient. If the distance of the bead to its attached position  $|\mathbf{r}_i^m - \mathbf{r}_i^{m-0}| >$   
 422  $0.5a$ , we assume that the bead breaks away from its attached position and acquires a new attached  
 423 position which is its current position, i.e.,  $\mathbf{r}_i^{m-0} = \mathbf{r}_i^m$ . The second term is the interaction between the  
 424 beads themselves, which we consider having short-range repulsion to avoid the overlap and mid-range  
 425 (two bead size) attraction, and no long-range (greater than two bead size) interaction<sup>14</sup>:

$$426 \quad u_{ij}^m = \begin{cases} \epsilon \left( \left( \frac{a}{r_{ij}} \right)^2 - 1 \right) \left( \left( \frac{r_c}{r_{ij}} \right)^2 - 1 \right)^2 & \text{for } r_{ij} \leq r_c ; \\ 0 & \text{for } r_{ij} > r_c \end{cases}$$

427 where  $r_c = 2a$ ; the third term is due to the repulsive interaction between the bead and the cell of  
 428 diameter ' $a$ ' to avoid the overlap and that to be harmonic:

$$429 \quad u_{ik}^{tm} = \begin{cases} k_{tm} (r_{ik} - a)^2 & \text{for } r_{ik} < a \\ 0 & \text{for } r_{ik} \geq a \end{cases}$$

430 where  $r_{ij} = |\mathbf{r}_j^m - \mathbf{r}_i^m|$  is the distance between the bead ' $i$ ' and ' $j$ ' and  $r_{ik} = |\mathbf{r}_k^t - \mathbf{r}_i^m|$  is the distance  
 431 between the cell ' $k$ ' and matrix bead ' $i$ '.

## 432 Initial Setup

433 We start with a spherical ball of cells of radius  $R_0 = 4a$ , which is made of 79 cells (except mentioned  
434 otherwise) and these cells are uniformly, randomly distributed within the spherical ball. This spherical  
435 ball of cells is surrounded by a concentric spherical shell of matrix of inner radius  $R_{in} = 5a$  and outer  
436 radius  $R_{out} = 12a$ , which is made of 6330 beads (except mentioned otherwise) and these beads are  
437 tightly packed in an orderly fashion on the surface of a sphere with radius ' $ka'$ ' ( $k \in [R_{in} - R_{out}]$ ) within  
438 the spherical shell. We keep the tissue viscosity  $\mu_t$  fixed for all the simulations except at the very end. We  
439 vary the matrix viscosity such that the viscosity ration  $\mu = \frac{\mu_t}{\mu_m} = 0.002$  and 2 for the viscoelastic and the  
440 elastic case, respectively. To change the stiffness, we vary the matrix elasticity coefficient  $G' =$   
441 05, 50, & 100 for the soft, intermediate, and stiff case, respectively, varying the matrix relaxation time  
442  $\tau_m = \frac{\mu_m}{G'}$ . To accommodate the linear relationship between the stiffness and the random motility of the  
443 cells, we use a linear relationship between stiffness and motility, and for three different stiffness of the  
444 matrix, we use the cell motility parameter  $M = 0.2, 0.8, \& 1.6$  for the soft, intermediate, and stiff matrix  
445 case, respectively. For the intermediate viscoelastic matrix, *i.e.*,  $\mu_m = 10, G' = 50$ , and the stiff  
446 viscoelastic case, *i.e.*,  $\mu_m = 10, G' = 100$ , the proliferation is high and long branches of the tissue exceed  
447 the matrix environment, to prevent this we used a thicker matrix with outer radius of the spherical shell  
448  $R_{out} = 14 \& 20$ , respectively. We used 10,240 & 30,710 beads in the matrix for the intermediate and stiff  
449 viscoelastic cases, respectively. For the stiff viscoelastic matrix case the proliferation is significantly high  
450 (Fig. 3c,j) and even with this thick matrix of size  $R_{out} = 20$ , with 30,710 beads, we could capture the  
451 correct physics only up to time  $\sim 180 \tau_g$ , and the simulations after this time show that the branches of  
452 tissues started to outgrow the matrix size. We did more than one simulation for all the six matrix cases  
453 mentioned above, *i.e.*, soft elastic & viscoelastic; intermediate elastic & viscoelastic; stiff elastic &  
454 viscoelastic; and they show statistically similar behavior.



455 For the case where we inhibit the cell motility, we use a very small motility parameter  $M = 0.01$ , for all  
456 the six conditions. For the case, where we inhibit the cell proliferation, we have used a slightly higher  
457 number of cells, i.e., 113, to start with a densely packed the spherical ball of the cells, as the number of  
458 cells will not increase with time. We performed two sets of simulation with the six conditions of matrix,  
459 for the cases where motility has been inhibited and where proliferation has been inhibited.

#### 460 **Simulations for phase diagram**

461 To explore the regimes of morphological stability, in terms of the three dimensionless parameter, we  
462 change the tissue viscosity ratio  $\mu = \frac{\mu_t}{\mu_m}$  from 0.001 – 2. For each case of tissue viscosity ratio  $\mu$ , we  
463 consider three cases of stiffness, i.e.,  $G' = 5, 50, \& 100$ , and perform the simulations. Since, the cell  
464 proliferation is an indirect function matrix rheology, the scaled cell flux  $j = \frac{\tau_g}{\tau_t}$  is an emergent parameter,  
465 recalling  $\tau_t$  is the time it takes to add one cell to the tissue. We observe both in experiments and  
466 simulations that as we decrease the matrix viscosity  $\mu_m$  and increase the matrix stiffness  $G'$ , cell  
467 proliferation increases and hence cell flux  $j$  increases. In our experiments the highest cell proliferation  
468 occurs in the Stiff Viscoelastic matrix and using linear regression we estimate that the tissue doubles in  
469 size in 20.5hr. This corresponds to value of  $\tau_t \sim 37s$  in the stiff viscoelastic matrices; in contrast,  $\tau_t \sim 330s$   
470 in stiff elastic matrices due to its much slower tissue growth. These are in the same order of magnitude  
471 of the relaxation times of the matrices. The resulting cell flux, when the initial spheroid is composed of  
472 2000 cells, is  $j = 0.027$ . For the stiff elastic case,  $j = 0.0030$ .

473 To generate the phase-diagram we developed a custom Matlab software and used support vector  
474 machines (SVM) classifier for binary classification. For the cases where motility is small, thence the  
475 proliferation is small, i.e.,  $j \sim 0$ , the growth of the spheroidal tissue for all the conditions were stable. We  
476 have plotted the corresponding two-dimensional phase-diagram (Extended Data Fig.13b) and the  
477 background looks completely blue, an indicator that the tissue growth for the scaled cell flux  $j \sim 0$  is always

478 stable. The data from actual simulations were represented as blue dots. For moderate values of scaled  
479 cell flux  $j \sim O(1)$ , we have plotted a three-dimensional phase diagram (Fig 3i, Extended Data Fig.13a). We  
480 observe that as the scaled proliferation increases the region of stability starts to shrink in  $\mu - A$  plane and  
481 eventually the whole phase space becomes unstable.

#### 482 **Controlled cell flux driven simulations**

483 For the controlled cell flux driven tissue growth, we relax the stress dependent cell proliferation condition.  
484 With this relaxed constraint, we add one cell (mass) after time  $\tau_t$  at the center of the tissue to mimic the  
485 experiments, where the cell flux injection is controlled and new cells (mass) are being added at the center  
486 of the tissue. By controlling  $\tau_t$  we can control the cell flux injection rate, which gives us a precise control  
487 over scaled cell flux  $j$ . This was not the case for stress dependent cell proliferation simulations. We vary  
488 the proliferation time scale  $\tau_t \in [0.1 - 1]$  to control the scaled cell flux  $j$ .

489 Using the data from our simulations we have generated a two-dimensional Phase-diagram (Extended Data  
490 Fig.13c) for the controlled flux driven case. We have fixed the scaled cell flux  $j = 10$ , and varied the  
491 viscosity ratio  $\mu \in [0.1 - 10]$  for the three values of elasticity  $G' = 0$  (to mimic the viscous Saffman-Taylor  
492 instability<sup>15</sup>), 0.1 (softer than the control soft matrix case), and 5 (soft matrix). The phase-diagram  
493 (Extended Data Fig.13c) shows an opposite trend where the region close to origin (elastic matrices,  
494 Extended Data Fig. 11d,e) becomes unstable and the region away from origin (viscoelastic matrices,  
495 Extended Data Fig. 11d,e) becomes stable. The data from actual simulations were represented as blue  
496 dots for spheroidal growth of the tissue and red dots for the branched growth of the tissue.

#### 497 **Simulation Methods**

498 We developed an inhouse Fortran-90 code to model the growth of spheroids in a viscoelastic matrix. The  
499 simulations were performed using the Euler-Maruyama method with a Langevin term and integrating in  
500 time. We use reduced, dimensionless unit, all lengths in terms of typical cell size ' $a$ ',  $r^* = r/a$ ; and all the

501 time in terms of cell proliferation time  $\tau_g$ ;  $t^* = t/\tau_g$ . We use Mersenne Twister algorithm, a  
502 pseudorandom number generator, to generate the random numbers.

### 503 **Quantification of tissue shape properties of simulations**

504 A custom MATLAB software was developed to measure, during the simulations, the tissue shape  
505 properties. Briefly, as the simulations are performed assuming that cells are discrete points, we first  
506 spherically dilate each point to generate a continuous volume. Then, once we have the connected mesh,  
507 the volume and sphericity are quantified. The area and circularity were quantified from the middle plane  
508 of the spheroid.

509

510 **Extended Data Table 1.** Alginate hydrogel composition.

Alginate Molecular weight (kDa)	Stiffness (Pa)	Alginate (%)	Calcium sulphate (mM)
138	390	2	16.8
138	1855	2	28.8
138	4959	2	57.6
38	409	2	33.6
38	1618	2	52.8
38	5095	2	96

511

512 **Extended Data Table 2.** Alginate-matrigel interpenetrating networks composition.

Alginate Molecular weight (kDa)	Stiffness (Pa)	Alginate (%)	Matrigel (mg/ml)	Calcium sulfate (mM)
138	473	1	5	26.4
138	1489	1	5	48
38	452	1	5	48
38	1422	1	5	96

513

514

515 **Extended Data Table 3.** Table for dimensionless quantities in the simulation.

Parameter	Simulations	Experiments
Cell Size (a)	$10^{-5}\text{m}$	$\sim 10^{-5}\text{m}$
Motility Speed ( $v_{\text{mig}} = \frac{D}{a}$ )	$1 \times 10^{-9} - 1 \times 10^{-6} \text{ m/s}$	$\sim 5 \times 10^{-8} \text{ m/s}$
Activity Time Scale ( $\tau_a = \frac{M}{\epsilon} \tau_g$ )	7-54 s	$\sim 2-40\text{s}^{16-18}$
Viscoelastic Time Scale ( $\tau_m = \frac{G'}{\mu_m}$ )	0.5-1000 s	30-350 s
Viscosity Ratio ( $\mu = \frac{\mu_t}{\mu_m}$ )	0.001-2	0.00019-0.066
Scaled Activity ( $A = \frac{\tau_a}{\tau_m}$ )	0.1-100	0.028-40
Scaled Cell Flux ( $j = \frac{\tau_g}{\tau_t}$ )	0.002-10	$\sim 0.003-166$

516

517 **References:**

- 518 1 Rowley, J. A., Madlambayan, G. & Mooney, D. J. Alginate hydrogels as synthetic extracellular  
519 matrix materials. *Biomaterials* **20**, 45-53 (1999).
- 520 2 Chaudhuri, O. *et al.* Hydrogels with tunable stress relaxation regulate stem cell fate and activity.  
521 *Nature materials* **15**, 326-334, doi:10.1038/nmat4489 (2016).
- 522 3 Chaudhuri, O. *et al.* Substrate stress relaxation regulates cell spreading. *Nature communications*  
523 **6**, 6364, doi:10.1038/ncomms7365 (2015).
- 524 4 Darnell, M. *et al.* Material microenvironmental properties couple to induce distinct  
525 transcriptional programs in mammalian stem cells. *Proceedings of the National Academy of*  
526 *Sciences of the United States of America* **115**, E8368-E8377, doi:10.1073/pnas.1802568115  
527 (2018).
- 528 5 Huebsch, N. *et al.* Harnessing traction-mediated manipulation of the cell/matrix interface to  
529 control stem-cell fate. *Nature materials* **9**, 518-526, doi:10.1038/nmat2732 (2010).
- 530 6 Zhao, X., Huebsch, N., Mooney, D. J. & Suo, Z. Stress-relaxation behavior in gels with ionic and  
531 covalent crosslinks. *J Appl Phys* **107**, 63509, doi:10.1063/1.3343265 (2010).
- 532 7 Debnath, J., Muthuswamy, S. K. & Brugge, J. S. Morphogenesis and oncogenesis of MCF-10A  
533 mammary epithelial acini grown in three-dimensional basement membrane cultures. *Methods*  
534 **30**, 256-268 (2003).
- 535 8 Berthier, L. & Kurchan, J. Non-equilibrium glass transitions in driven and active matter. *Nature*  
536 *Physics* **9**, 310-314, doi:10.1038/nphys2592 (2013).
- 537 9 Mallory, S. A., Šarić, A., Valeriani, C. & Cacciuto, A. Anomalous thermomechanical properties of a  
538 self-propelled colloidal fluid. *Physical Review E* **89**, 052303, doi:10.1103/PhysRevE.89.052303  
539 (2014).

540 10 Wang, X., Ramírez-Hinestrosa, S., Dobnikar, J. & Frenkel, D. The Lennard-Jones potential: when  
541 (not) to use it. *Physical Chemistry Chemical Physics* **22**, 10624-10633, doi:10.1039/C9CP05445F  
542 (2020).

543 11 Kardar, M. *Statistical Physics of Fields*. (Cambridge University Press, 2007).

544 12 Uroz, M. *et al.* Regulation of cell cycle progression by cell-cell and cell-matrix forces. *Nature cell*  
545 *biology* **20**, 646-654, doi:10.1038/s41556-018-0107-2 (2018).

546 13 Delarue, M. *et al.* Compressive Stress Inhibits Proliferation in Tumor Spheroids through a  
547 Volume Limitation. *Biophysical journal* **107**, 1821-1828,  
548 doi:<https://doi.org/10.1016/j.bpj.2014.08.031> (2014).

549 14 Hastings, W. K. Monte Carlo Sampling Methods Using Markov Chains and Their Applications.  
550 *Biometrika* **57**, 97-109, doi:10.2307/2334940 (1970).

551 15 Saffman, P. G. & Taylor, G. I. The penetration of a fluid into a porous medium or Hele-Shaw cell  
552 containing a more viscous liquid. *Proceedings of the Royal Society of London. Series A.*  
553 *Mathematical and Physical Sciences* **245**, 312-329, doi:doi:10.1098/rspa.1958.0085 (1958).

554 16 Liu, Z. *et al.* Mechanical tugging force regulates the size of cell-cell junctions. *Proceedings of the*  
555 *National Academy of Sciences of the United States of America* **107**, 9944-9949,  
556 doi:10.1073/pnas.0914547107 (2010).

557 17 Maruthamuthu, V., Sabass, B., Schwarz, U. S. & Gardel, M. L. Cell-ECM traction force modulates  
558 endogenous tension at cell-cell contacts. *Proceedings of the National Academy of Sciences of the*  
559 *United States of America* **108**, 4708-4713, doi:10.1073/pnas.1011123108 (2011).

560 18 Maitre, J. L. & Heisenberg, C. P. The role of adhesion energy in controlling cell-cell contacts.  
561 *Current opinion in cell biology* **23**, 508-514, doi:10.1016/j.ceb.2011.07.004 (2011).

562